Ketamine shows long‐term benefit in patients with treatment‐resistant depression
The Brown University Psychopharmacology Update · 2026-05 · 37 (5) · 3-3
DOI: 10.1002/pu.31440 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 08.04.2026.
Themen: Depression
Abstract (Originalsprache)
Patients with treatment‐resistant depression who received a series of treatments with ketamine or esketamine showed a substantial reduction in emergency department visits related to suicidality over a 6‐month period, a study has found. Study participants had a 56.7% response rate of depression symptoms following the acute phase of treatment.
Zitieren
APA
(2026). Ketamine shows long‐term benefit in patients with treatment‐resistant depression. The Brown University Psychopharmacology Update, 37(5), 3-3. https://doi.org/10.1002/pu.31440
Vancouver
Ketamine shows long‐term benefit in patients with treatment‐resistant depression. The Brown University Psychopharmacology Update. 2026;37(5):3-3. doi:10.1002/pu.31440
BibTeX
@article{euvimed2026,
title = {Ketamine shows long‐term benefit in patients with treatment‐resistant depression},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {5},
pages = {3--3},
doi = {10.1002/pu.31440}
}
EUVIMED